Overview

Apixaban for Treatment of Embolic Stroke of Undetermined Source

Status:
Completed
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Multicentre (national, Germany), randomized (2x2 factorial), open, parallel group, active controlled, efficacy study (phase III)
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital Tuebingen
Collaborators:
Bristol-Myers Squibb
Medtronic
ZKS and IKEaB Tübingen
Treatments:
Apixaban
Aspirin
Salicylic Acid